[go: up one dir, main page]

CY1114209T1 - Φαρμακευτικες και καλλυντικες συνθεσεις που περιλαμβανουν plgf-1 - Google Patents

Φαρμακευτικες και καλλυντικες συνθεσεις που περιλαμβανουν plgf-1

Info

Publication number
CY1114209T1
CY1114209T1 CY20131100692T CY131100692T CY1114209T1 CY 1114209 T1 CY1114209 T1 CY 1114209T1 CY 20131100692 T CY20131100692 T CY 20131100692T CY 131100692 T CY131100692 T CY 131100692T CY 1114209 T1 CY1114209 T1 CY 1114209T1
Authority
CY
Cyprus
Prior art keywords
cosmetic compositions
pharmaceutical
compositions containing
plgf
connective tissue
Prior art date
Application number
CY20131100692T
Other languages
English (en)
Inventor
Domenico Maglione
Mauro Battisti
Ettore Conti
Giuseppe Salvia
Marina Tucci
Original Assignee
Geymonat S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11456138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114209(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geymonat S.P.A. filed Critical Geymonat S.P.A.
Publication of CY1114209T1 publication Critical patent/CY1114209T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση σχετίζεται με την παρασκευή θεραπευτικών και καλλυντικών συνθέσεων που περιλαμβάνουν πλακουντιακό αυξητικό παράγοντα (ΡLGF-1) οι οποίες δύνανται να αυξήσουν την αγγειογένεση του δερματικού, του υποδόριου συνδετικού ιστού και του συνδετικού ιστού εσωτερικών οργάνων. Τέτοιες συνθέσεις είναι κατάλληλες για την αγωγή έναντι παθολογικών ή φυσικών καταστάσεων που ωφελούνται από τον σχηματισμό ή την αναγέννηση νέων αγγείων του δέρματος, όπως το σκληρόδερμα, οι διάφορες εκδηλώσεις αυτού, η γήρανση του δέρματος, ή η τριχόπτωση.
CY20131100692T 2002-03-05 2013-08-13 Φαρμακευτικες και καλλυντικες συνθεσεις που περιλαμβανουν plgf-1 CY1114209T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002RM000119A ITRM20020119A1 (it) 2002-03-05 2002-03-05 Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
EP03712652.1A EP1482967B1 (en) 2002-03-05 2003-03-05 Pharmaceutical and cosmetic compositions comprising plgf-1

Publications (1)

Publication Number Publication Date
CY1114209T1 true CY1114209T1 (el) 2016-08-31

Family

ID=11456138

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100692T CY1114209T1 (el) 2002-03-05 2013-08-13 Φαρμακευτικες και καλλυντικες συνθεσεις που περιλαμβανουν plgf-1

Country Status (20)

Country Link
US (1) US7364722B2 (el)
EP (1) EP1482967B1 (el)
JP (2) JP5010093B2 (el)
KR (1) KR100988656B1 (el)
CN (1) CN100467058C (el)
AU (1) AU2003217464B2 (el)
BR (1) BR0308040A (el)
CA (1) CA2477075C (el)
CY (1) CY1114209T1 (el)
DK (1) DK1482967T3 (el)
ES (1) ES2424827T3 (el)
HR (1) HRP20040914A2 (el)
IT (1) ITRM20020119A1 (el)
MX (1) MXPA04008486A (el)
PL (1) PL371788A1 (el)
PT (1) PT1482967E (el)
RU (1) RU2292906C2 (el)
SI (1) SI1482967T1 (el)
WO (1) WO2003074075A1 (el)
ZA (1) ZA200407707B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872040B1 (fr) * 2004-06-23 2006-09-22 Centre Nat Rech Scient Cnrse Utilisation cosmetique d'au moins un tetrapeptide naturel ac-n-ser-asp-lys-pro- ou un de ses analogues en tant qu'agent antivieillissement et restructurant de la peau
US8057458B2 (en) * 2006-10-30 2011-11-15 Warsaw Orthopedic, Inc. Method for treating facet pain
CA2750559A1 (en) * 2009-02-05 2010-08-12 Digna Biotech, S.L. Pharmaceutical formulations of tgf-.beta.1 inhibitor peptides
EP2456784B1 (en) 2009-07-24 2017-01-11 Advanced Accelerator Applications S.A. Compounds modulators of vegf activity and uses thereof
EP2948164B1 (en) * 2013-01-28 2019-04-10 Shire Human Genetic Therapies, Inc. Placenta growth factor in treating duchenne muscular dystrophy
WO2015109329A1 (en) 2014-01-17 2015-07-23 Mimedx Group, Inc. Method for inducing angiogenesis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1283892A (en) * 1970-06-08 1972-08-02 Irwin Irville Lubowe Improvements in and relating to medicinal compositions for application to the skin and/or hair
IT1242149B (it) 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
CA2229479C (en) * 1995-08-15 2010-03-30 Connective Therapeutics, Inc. Method of promoting angiogenesis
RU2102091C1 (ru) * 1995-09-19 1998-01-20 Казанский медицинский университет Способ лечения системной склеродермии
WO1997048405A1 (fr) * 1996-06-21 1997-12-24 Jury Evgenievich Belyaev Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes
US7947472B2 (en) * 1997-12-24 2011-05-24 Vegenics Limited Expression vectors and cell lines expressing vascular endothelial growth factor D
WO2001000792A1 (en) * 1999-06-29 2001-01-04 Marchosky J Alexander Compositions and methods for forming and strengthening bone
JP3877914B2 (ja) * 1999-09-07 2007-02-07 サンスター株式会社 皮膚化粧料
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
JP2001316242A (ja) * 2000-03-02 2001-11-13 Noevir Co Ltd 皮膚外用剤
JP2004500409A (ja) * 2000-03-31 2004-01-08 ザ　ジェネラル　ホスピタル　コーポレーション 毛の成長を調節する方法

Also Published As

Publication number Publication date
BR0308040A (pt) 2004-12-14
ZA200407707B (en) 2005-07-27
JP2005519101A (ja) 2005-06-30
CA2477075A1 (en) 2003-09-12
RU2004129586A (ru) 2005-06-10
CA2477075C (en) 2013-08-06
PL371788A1 (en) 2005-06-27
KR100988656B1 (ko) 2010-10-18
HRP20040914A2 (en) 2004-12-31
JP5010093B2 (ja) 2012-08-29
US20050075288A1 (en) 2005-04-07
US7364722B2 (en) 2008-04-29
SI1482967T1 (sl) 2013-10-30
MXPA04008486A (es) 2005-04-19
KR20040111379A (ko) 2004-12-31
PT1482967E (pt) 2013-08-27
WO2003074075A1 (en) 2003-09-12
JP2010116405A (ja) 2010-05-27
HK1078469A1 (zh) 2006-03-17
ITRM20020119A0 (it) 2002-03-05
CN1638793A (zh) 2005-07-13
ES2424827T3 (es) 2013-10-08
CN100467058C (zh) 2009-03-11
US20050239698A2 (en) 2005-10-27
AU2003217464A1 (en) 2003-09-16
ITRM20020119A1 (it) 2003-09-05
EP1482967A1 (en) 2004-12-08
RU2292906C2 (ru) 2007-02-10
JP5144690B2 (ja) 2013-02-13
AU2003217464B2 (en) 2007-08-30
EP1482967B1 (en) 2013-05-15
DK1482967T3 (da) 2013-08-26

Similar Documents

Publication Publication Date Title
CY1114209T1 (el) Φαρμακευτικες και καλλυντικες συνθεσεις που περιλαμβανουν plgf-1
EA200800368A1 (ru) Гликозилированный il-7, получение и применение
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
WO2004061456A3 (de) Verwendungen von hmgb, hmgn, hmga proteinen
RU2008115678A (ru) Пептиды, способные связываться с трансформирующим фактором роста бета 1 (tgf-бета 1)
DE60035337D1 (de) Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoide Tumorzellen, herbeiführen oder bewirken
CY1116633T1 (el) Χρηση αναστολεων πεπτιδιου του μονοπατιου μεταγωγης σηματος jnk οι οποιοι διαπερνουν τα κυτταρα για τη θεραπευτικη αγωγη διαφορων καρδιαγγειακων νοσων
ATE446313T1 (de) Muteine von tränen-lipocalin
NO20006078L (no) N-bundete sulfen-amider av N-heterocykliske karboksylsyrer eller karboksylsyre-isostere
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
ATE386800T1 (de) Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
DK0910647T3 (da) Human DNase i hyperaktive varianter
NO20063064L (no) Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte
DK1000149T3 (da) 5'-EST'ere til udskilte proteiner identificeret fra hjernevæv
DE69840497D1 (de) Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen
DK1390403T3 (da) Peptider afledt af nervetrådsproteiner og medicinsk anvendelse deraf
CY1106746T1 (el) Χρηση του irbesartan για την προληψη ή τη θεραπεια της πνευμονικης υπερτασης
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
DK0434057T3 (da) Indocarbazol-derivater, fremgangsmåder til deres fremstilling og deres anvendelse
ATE527377T1 (de) Erstellung von genexpressionprofilen aus ffpe- proben
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
DE602005013788D1 (de) ckrox-Peptide und ihre Analoge zur Behandlung von Hautalterung
MX2025009372A (es) Proteinas/peptidos de fusion, metodos y usos de los mismos
ATE482976T1 (de) Defensinproteine
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung